Post Mastectomy Reconstruction denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for post mastectomy reconstruction are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Post-Mastectomy Reconstruction as Not FDA-Approved

A not-FDA-approved denial in the context of post-mastectomy reconstruction usually signals one of two things: either the denial applies to a specific implant device or material that has not received FDA marketing authorization, or the denial is an administrative error that misclassified a surgical procedure under a coverage exclusion intended for investigational drugs or devices. Surgical techniques themselves are not FDA-approved in the way drugs are — surgeons are generally free to perform procedures using their clinical judgment — but the devices used (such as breast implants or tissue matrices) do require FDA clearance or approval.

If the denial targets a specific device, your appeal needs to confirm FDA authorization status for that device and establish its clinical appropriateness. If the denial is a misclassification of the surgical procedure itself, the appeal is primarily administrative and should invoke the Women's Health and Cancer Rights Act (WHCRA) of 1998, which requires plans to cover post-mastectomy reconstruction without carving out FDA-approval conditions that the statute does not contemplate.

## Why It Is Appealable

Most breast implants and acellular dermal matrices used in reconstruction have FDA clearance or approval. If your surgeon chose a specific device, your appeal can document its regulatory status directly. More broadly, WHCRA's mandate for reconstruction coverage is not conditioned on a device-by-device FDA review; the statute operates at the level of the reconstructive procedure category.

## Federal Appeal Framework

• Internal appeal (ACA §2719 / ERISA §503): Submit your internal appeal within the timeframe on the denial notice. Ask the insurer to identify precisely which device or element it considers not-FDA-approved.
• External review (ACA §2719): After exhausting internal appeal, you have approximately four months from the final denial to request independent external review.
• Expedited review: Request simultaneously with your internal appeal if your surgery is time-sensitive or delay creates clinical risk.

## Concrete Appeal Steps and Timeline

1. Contact BCBS and request the specific denial rationale: which device or procedure element was flagged, and under which policy provision. 2. Ask your surgeon or the device manufacturer to provide FDA clearance/approval documentation for any implant or material being used. 3. Assemble the appeal packet and submit by the deadline. 4. If denied internally, proceed immediately to external review.

## Documentation to Gather

• Device FDA documentation: The 510(k) clearance summary or PMA approval letter for any implant or tissue matrix involved, obtainable from the FDA's public device database or from the manufacturer.
• Surgeon's letter: A letter from your plastic surgeon identifying the specific devices planned, confirming their regulatory status, and explaining the clinical rationale for their use.
• Mastectomy and diagnosis records: Pathology report and operative notes establishing the clinical context.
• Denial letter and policy language: The exact policy provision BCBS cited, so you can respond to each element specifically.
• WHCRA citation: Invoke the federal statute and note that it does not permit plans to deny reconstruction through device-approval exclusions not contemplated by the law.

## Criteria-Mapping Structure

Obtain BCBS's published medical/coverage policy and its definition of "not FDA-approved" as applied to this context. List each criterion. For each one, provide the specific evidence — FDA database reference, surgeon attestation, or clinical record — that addresses it directly. If the denial was a misclassification, state that clearly at the top of your mapping section and explain why the policy provision does not apply.